Market Cap: $2.6762T -1.240%
Volume(24h): $130.1449B 61.270%
  • Market Cap: $2.6762T -1.240%
  • Volume(24h): $130.1449B 61.270%
  • Fear & Greed Index:
  • Market Cap: $2.6762T -1.240%
Cryptos
Topics
Cryptospedia
News
CryptosTopics
Videos
Top News
Cryptos
Topics
Cryptospedia
News
CryptosTopics
Videos
bitcoin
bitcoin

$83571.608249 USD

-1.38%

ethereum
ethereum

$1826.028236 USD

-3.02%

tether
tether

$0.999839 USD

-0.01%

xrp
xrp

$2.053149 USD

-2.48%

bnb
bnb

$601.140115 USD

-0.44%

solana
solana

$120.357332 USD

-3.79%

usd-coin
usd-coin

$0.999833 USD

-0.02%

dogecoin
dogecoin

$0.166175 USD

-3.43%

cardano
cardano

$0.652521 USD

-3.00%

tron
tron

$0.236809 USD

-0.59%

toncoin
toncoin

$3.785339 USD

-5.02%

chainlink
chainlink

$13.253231 USD

-3.91%

unus-sed-leo
unus-sed-leo

$9.397427 USD

-0.19%

stellar
stellar

$0.266444 USD

-1.00%

sui
sui

$2.409007 USD

1.15%

Cryptocurrency News Articles

Cathie Wood Buys $7.8 Million of Moderna Vaccine Stock, Betting on Diversified Pipeline and Regulatory Wins

Mar 27, 2024 at 10:30 am

On Tuesday, Cathie Wood's Ark Invest significantly increased its stake in Moderna Inc. (MRNA), a prominent COVID-19 vaccine manufacturer, amid a series of upcoming catalysts for the biotech firm. Ark Invest purchased 72,800 shares of Moderna through its flagship Ark Innovation ETF (ARKK), valued at approximately $7.82 million. This move indicates Ark Invest's continued confidence in Moderna's potential beyond its mRNA COVID-19 vaccine, including a next-gen COVID-19 vaccine and other promising candidates.

Cathie Wood Buys $7.8 Million of Moderna Vaccine Stock, Betting on Diversified Pipeline and Regulatory Wins

Why Cathie Wood Just Bought $7.8 Million Worth of This COVID-19 Vaccine Stock

Embracing a "buy the dip" mentality, Cathie Wood's Ark Invest has significantly boosted its stake in Moderna Inc., a leading COVID-19 vaccine producer, with a strategic purchase of 72,800 shares. Priced at $107.41 each, this acquisition represents an investment of approximately $7.82 million.

Betting on Moderna's Diversified Pipeline

Ark Invest's enthusiasm for Moderna extends beyond the firm's mRNA COVID-19 vaccine. The investment firm sees immense potential in Moderna's broader pipeline, including a next-generation COVID-19 vaccine and promising candidates in various therapeutic areas.

Riding the Regulatory Wave

With expectations of vaccine approvals and upcoming investor events, Ark Invest anticipates Moderna's stock to soar despite its recent market underperformance. Moderna's stock has declined by 26.89% over the past 12 months, but has rebounded by 8% since the start of 2024.

Other Notable Trades

In addition to the Moderna purchase, ARKG, Ark's genomic revolution ETF, has shed 1,770 shares of Nvidia Corp. Valued at $1.63 million, this move signals a shift in focus within the ETF's portfolio.

Meanwhile, ARKF, Ark's fintech innovation ETF, has acquired shares of Roblox Corp., while ARKG has expanded its holdings in Recursion Pharmaceuticals with a purchase of 60,9626 shares. On the other hand, ARKQ, Ark's autonomous technology and robotics ETF, has sold shares of Trimble Inc.

Disclaimer:info@kdj.com

The information provided is not trading advice. kdj.com does not assume any responsibility for any investments made based on the information provided in this article. Cryptocurrencies are highly volatile and it is highly recommended that you invest with caution after thorough research!

If you believe that the content used on this website infringes your copyright, please contact us immediately (info@kdj.com) and we will delete it promptly.

Other articles published on Apr 03, 2025